In my recent research, I delved into the economics of Mebendazole, a drug commonly used to treat parasitic infections. I discovered that while Mebendazole is quite affordable, the overall cost of parasite treatment can vary depending on factors such as the severity of the infection, accessibility to healthcare, and the availability of generic alternatives. It's important to note that the costs associated with untreated parasitic infections, including lost productivity and long-term health issues, can be significantly higher than the treatment costs. I believe that increasing awareness of affordable treatment options like Mebendazole, as well as improving access to healthcare, can play a crucial role in minimizing the financial burden of parasitic infections.